Replies to post #110545 on Biotech Values

[masterlongevity]

slides on ocrelizumab are interesting.. it looks like they are going after PPMS as well as RRMS..


Can someone post slide 92 on IHUB. Dew? This show the RRMS relapse reduction rates across all MS therapies, those on the market and in ph2/3.

Interestingly, ocrelizumab has the best efficacy, although we all know you can't make direct comparisons :)